Innohep (Tinzaparin Sodium)

Tinzaparin sodium binds to antithrombin III, accelerating its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This reduces thrombin generation and fibrin clot formation, preventing new clots and limiting growth of existing ones.

The dosing regimen for Innohep is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and risk factors. The prescriber determines the appropriate sub‑cutaneous dose and frequency in accordance with current clinical guidelines.

Tinzaparin sodium is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used when the benefit outweighs potential risk, but clinicians should evaluate each case. Limited data are available for breastfeeding; a risk‑benefit assessment is recommended.

To request Innohep, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Compared with unfractionated heparin, tinzaparin offers more predictable pharmacokinetics, once‑daily sub‑cutaneous dosing, and lower monitoring requirements. Relative to other low‑molecular‑weight heparins, tinzaparin has a slightly longer half‑life and a higher anti‑Xa to anti‑IIa activity ratio, which may influence dosing in renal impairment.

Innohep should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vials in the original packaging until use, and discard any solution that appears discolored or contains particles.

Innohep is supplied as a sterile injectable solution for sub‑cutaneous injection. The injection is typically given in the abdominal wall or thigh, using a suitable needle, and the site should be rotated to reduce local irritation. Administration is performed by trained healthcare personnel following aseptic technique.

The most serious adverse events include major bleeding, such as gastrointestinal or intracranial hemorrhage, and heparin‑induced thrombocytopenia (HIT), an immune‑mediated reaction that can paradoxically increase clot risk. Prompt recognition and discontinuation are essential if these events occur.

Innohep is contraindicated in patients with known hypersensitivity to tinzaparin or any heparin product, active major bleeding, or a history of heparin‑induced thrombocytopenia. Caution is also advised in severe renal impairment, uncontrolled hypertension, and in patients undergoing neuraxial anesthesia.